61352 Bad Homburg, de
+49 (6172) 608-2872
Fresenius appoints Rachel Empey as Chief Financial Officer
Rachel Empey has been Chief Financial and Strategy Officer of Telefónica Deutschland Holding AG (“Telefónica Deutschland”) since 2011. Telefónica Deutschland is listed on the Frankfurt Stock Exchange and, with a market capitalization of more than €12 billion, is a leading TecDAX constituent. Before joining the Management Board of Telefónica Deutschland, Rachel Empey held a number of key international finance and controlling positions in the Telefónica group. She started her career as an auditor at Ernst & Young and business analyst at Lucent Technologies. Rachel Empey is British, a Chartered Accountant and holds an MA (Hons) in Mathematical Sciences from the University of Oxford.
Dr. Gerd Krick, Chairman of Fresenius Management SE’s Supervisory Board, said: “We are pleased to welcome a true financial expert and highly experienced manager as our new CFO. Among all the excellent candidates for this position, Rachel Empey impressed us with her exceptional technical expertise, sound strategic thinking and successful track record. She is a great addition to our proven management team.”
Stephan Sturm said: “I am very much looking forward to working with Rachel Empey. She is going to be the perfect fit for our Management Board. Along with first-rate qualifications and skills, wide-ranging experience and an engaging personality, she will bring new insights to Fresenius from another dynamic and innovative industry.”
Rachel Empey said: “I am very excited to be joining Fresenius and taking up this tremendous professional opportunity. Fresenius has a very strong position in the healthcare industry. I look forward to contributing to the company’s continued growth and consistent success as Chief Financial Officer.”
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an firstname.lastname@example.org.